CRESTOR

LOE ApproachingSM

rosuvastatin

NDAORALTABLET
Approved
Aug 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

HMG‑CoA reductase, the rate-limiting enzyme that converts 3‑hydroxy‑3‑methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.

Clinical Trials (5)

NCT07431866Phase 1Not Yet Recruiting

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Started Apr 2026
39 enrolled
Healthy
NCT07446400Phase 1Not Yet Recruiting

A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together

Started Mar 2026
48 enrolled
Healthy Volunteers
NCT07316608Phase 1Not Yet Recruiting

A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Started Mar 2026
44 enrolled
Healthy Participants
NCT07372625Phase 1Not Yet Recruiting

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Started Jan 2026
NCT07349394Phase 1Active Not Recruiting

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

Started Jan 2026
18 enrolled
Cystic Fibrosis